Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director · Chief Executive Officer | March 10, 2026 | March 12, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date March 10, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,898,838 |
Reported balance
After 2026-03-10 transaction · row 1
1 source rowRow 1 · 2026-03-10 · Grant · Acquired 409,836 · Balance 1,898,838 F1: The restricted stock unit award, granted as an annual performance award, vests as to 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit award, granted as an annual performance award, vests as to 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 6,044 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 8,185 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,944 | Not disclosed Strike: $4.88 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 6 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,944 Underlying: Class A Common Stock · 4,944 shares Expires 2019-09-07 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F7 · derivative.exercise_date: The option vests as to 44,944 shares, as adjusted, upon the Issuer's achievement of a certain milestone. The remaining shares underlying the option are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 39,982 | Not disclosed Strike: $11.49 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 5 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,982 Underlying: Class A Common Stock · 39,982 shares Expires 2029-01-29 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,154 | Not disclosed Strike: $12.95 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,404 Underlying: Class A Common Stock · 11,154 shares Expires 2028-02-21 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,518 | Not disclosed Strike: $14.93 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,018 Underlying: Class A Common Stock · 8,518 shares Expires 2027-02-27 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,056 | Not disclosed Strike: $9.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,056 Underlying: Class A Common Stock · 4,056 shares Expires 2026-03-01 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F3 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2016. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 5,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,442 F1 · price: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received 5,133 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock units are subject to vesting conditions consistent with the terms of the existing Ironwood restricted stock units held by the reporting person prior to the Separation. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 16:53 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 14 | $14.32 | $200.48 |
DisclosureSEC source: 0001209191-19-012651 · doc4.xml · nonDerivative · entry 6 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,309 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 16:53 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 17 | $14.32 | $243.44 |
DisclosureSEC source: 0001209191-19-012651 · doc4.xml · nonDerivative · entry 5 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,323 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 16:53 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 10 | $14.32 | $143.20 |
DisclosureSEC source: 0001209191-19-012651 · doc4.xml · nonDerivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,340 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $14.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 16:53 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,631 | $14.31 | $23,339.61 |
DisclosureSEC source: 0001209191-19-012651 · doc4.xml · nonDerivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,350 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 16:53 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,957 | $14.31 | $28,004.67 |
DisclosureSEC source: 0001209191-19-012651 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,981 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 16:53 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,212 | $14.31 | $17,343.72 |
DisclosureSEC source: 0001209191-19-012651 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,938 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $14.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:33 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option(Right to Buy) · Derivative | 345,000 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006224 · doc4.xml · derivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,000 Underlying: Class A Common Stock · 345,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:47 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 7,500 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001179110-19-001062 · edgar.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-01-25 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:47 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001062 · edgar.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,045 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 20:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 130,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001501 · doc4.xml · derivative · entry 5 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Class A Common Stock · 130,000 shares Expires 2019-09-07 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · derivative.exercise_date: The option vests in four equal installments based on the issuer's achievement of certain regulatory and commercial milestones. Upon achievement of regulatory or commercial milestones, the option vested as to 40,000 shares of Class B Common Stock on each of October 24, 2011, December 21, 2012 and January 4, 2017. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 20:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 130,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001501 · doc4.xml · derivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 130,000 shares Expires 2019-09-07 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · derivative.exercise_date: The option vests in four equal installments based on the issuer's achievement of certain regulatory and commercial milestones. Upon achievement of regulatory or commercial milestones, the option vested as to 40,000 shares of Class B Common Stock on each of October 24, 2011, December 21, 2012 and January 4, 2017. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 20:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 130,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001501 · doc4.xml · derivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Class A Common Stock · 130,000 shares Expires 2019-09-07 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · derivative.exercise_date: The option vested as to 25% of the shares of Class B Common Stock on the first anniversary of September 8, 2009, and 1/48th of the shares of Class B Common Stock vest each month thereafter for the next 36 months. The option was fully vested as of September 8, 2013. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 20:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 130,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001501 · doc4.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 130,000 shares Expires 2019-09-07 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. In connection with the conversion, outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F2 · derivative.exercise_date: The option vested as to 25% of the shares of Class B Common Stock on the first anniversary of September 8, 2009, and 1/48th of the shares of Class B Common Stock vest each month thereafter for the next 36 months. The option was fully vested as of September 8, 2013. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 17:56 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045051 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,150 F1 · kind: The restricted stock unit award, granted as a recognition award, vests as to 100% of the shares of Class A Common Stock on May 9, 2019. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 17:18 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option(Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001209191-18-042183 · doc4.xml · derivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Class B Common Stock · 30,000 shares Expires 2019-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments based on the issuer's achievement of certain regulatory and commercial milestones. Upon achievement of regulatory or commercial milestones, the option vested as to 40,000 shares of Class B Common Stock on each of October 24, 2011, December 21, 2012 and January 4, 2017. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 17:18 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 30,000 | $20.00 | $600,000.00 |
DisclosureSEC source: 0001209191-18-042183 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 17:18 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 30,000 | $5.48 | $164,400.00 |
DisclosureSEC source: 0001209191-18-042183 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:21 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 7,500 | $0.00 Strike: $40.61 | $0.00 |
DisclosureSEC source: 0001179110-18-003507 · edgar.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-03-01 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:21 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003507 · edgar.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,795 Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 18:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option(Right to Buy) · Derivative | 131,250 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012582 · doc4.xml · derivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Class A Common Stock · 131,250 shares Expires 2028-02-21 F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 18:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-012582 · doc4.xml · nonDerivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,513 F5 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 18:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,917 | $14.66 | $28,103.22 |
DisclosureSEC source: 0001209191-18-012582 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,638 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 18:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,426 | $14.66 | $20,905.16 |
DisclosureSEC source: 0001209191-18-012582 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,555 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The reporting person acquired 1,681 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2017. Read SEC document |
| May 15, 2017 Filed May 16, 2017 18:22 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001209191-17-032868 · doc4.xml · derivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Class B Common Stock · 30,000 shares Expires 2019-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 25% of the shares of Class B Common Stock on the first anniversary of September 8, 2009, and 1/48th of the shares of Class B Common Stock vested on each monthly anniversary thereafter for the next 36 months. This option was fully vested as of September 8, 2013. Read SEC document |
| May 15, 2017 Filed May 16, 2017 18:22 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 30,000 | $18.20 | $546,000.00 |
DisclosureSEC source: 0001209191-17-032868 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.14 to $18.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 15, 2017 Filed May 16, 2017 18:22 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 30,000 | $5.48 | $164,400.00 |
DisclosureSEC source: 0001209191-17-032868 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 18:22 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 3,272 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001179110-17-004597 · edgar.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,272 Underlying: Common Stock · 3,272 shares Expires 2027-03-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 18:22 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 545 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004597 · edgar.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545 Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:28 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 157,500 | $0.00 Strike: $16.77 | $0.00 |
DisclosureSEC source: 0001209191-17-016107 · doc4.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Class A Common Stock · 157,500 shares Expires 2027-02-27 F2 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:28 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016107 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,300 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:36 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,520 | $16.94 | $25,748.80 |
DisclosureSEC source: 0001209191-17-014367 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,050 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.47 to $17.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: The reporting person acquired 2,258 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.